IRD Stock Analysis: Buy, Sell, or Hold?
IRD - Opus Genetics, Inc. Common Stock
$3.95
-0.13 (-3.15%)
▼
5d:
+1.32%
30d:
-7.24%
90d:
-12.38%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When IRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IRD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: IRD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: IRD is currently trading at $3.95, which is considered slightly low relative to its 30-day fair value range of $3.95 to $4.32.
Technical Outlook: Technically, IRD is in a strong uptrend. The price is currently testing key support at $3.88. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: IRD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.44 (+155.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRD is in a strong uptrend. The price is currently testing key support at $3.88. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: IRD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.44 (+155.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.95 -
$4.32
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 155.8% below Wall St target ($10.44)
Trading Range Analysis
30-Day Trading Range
$3.95 -
$4.32
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.88
Resistance Level
$4.68
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.76
Wall Street Target
$10.44
(+155.8%)
Revenue Growth (YoY)
-50.6%
Share & Embed Analysis
Last updated: June 24, 2026 10:21 AM ET
Data refreshes hourly during market hours. Next update: 11:21 AM
Data refreshes hourly during market hours. Next update: 11:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashwath Jayagopal
SELL
3719 shares
2026-03-16
George Magrath
SELL
24438 shares
2026-03-16
Joseph K Schachle
SELL
3719 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 65 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 61 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 61 BUY |